LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GSK 690693 | 10 | uM | LJP5 | 72 | hr | 1476 | 3105 | 3772 | 0.8233 | 0.7322 |
| SK-BR-3 | SNS-032 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1988 | 3643 | 0.5471 | 0.2581 |
| SK-BR-3 | SNS-032 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1006 | 3643 | 0.2765 | -0.2563 |
| SK-BR-3 | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 885 | 3643 | 0.2421 | -0.3287 |
| SK-BR-3 | SNS-032 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 905 | 3643 | 0.2485 | -0.3154 |
| SK-BR-3 | SNS-032 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 843 | 3643 | 0.2314 | -0.3514 |
| SK-BR-3 | SNS-032 | 10 | uM | LJP6 | 72 | hr | 1476 | 823 | 3643 | 0.2260 | -0.3633 |
| SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 1371 | 3643 | 0.3762 | -0.0579 |
| SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1324 | 3643 | 0.3644 | -0.0802 |
| SK-BR-3 | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1387 | 3643 | 0.3814 | -0.0476 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1506 | 3643 | 0.4131 | 0.0126 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1484 | 3643 | 0.4075 | 0.0023 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 72 | hr | 1476 | 1228 | 3643 | 0.3371 | -0.1337 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2714 | 3643 | 0.7452 | 0.5950 |
| SK-BR-3 | GSK1904529A | 0.12 | uM | LJP6 | 72 | hr | 1476 | 3161 | 3643 | 0.8668 | 0.7900 |
| SK-BR-3 | GSK1904529A | 0.37 | uM | LJP6 | 72 | hr | 1476 | 3597 | 3643 | 0.9863 | 0.9768 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 72 | hr | 1476 | 3473 | 3643 | 0.9541 | 0.9303 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 1476 | 3691 | 3643 | 1.0132 | 1.0203 |
| SK-BR-3 | GSK1904529A | 10 | uM | LJP6 | 72 | hr | 1476 | 3712 | 3643 | 1.0185 | 1.0276 |
| SK-BR-3 | Linsitinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2598 | 3772 | 0.6890 | 0.5187 |
| SK-BR-3 | Linsitinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 2930 | 3772 | 0.7771 | 0.6600 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3099 | 3772 | 0.8215 | 0.7294 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 2921 | 3772 | 0.7749 | 0.6560 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2842 | 3772 | 0.7536 | 0.6224 |
| SK-BR-3 | Linsitinib | 10 | uM | LJP5 | 72 | hr | 1476 | 2480 | 3772 | 0.6576 | 0.4667 |